Top Markets
#1 Islamic Coin Islamic Coin +151.48%
#2 DOVU DOVU +48.44%
#3 Black Phoenix Black Phoenix +34.78%
#4 Velvet Velvet +31.18%
#5 Cross Cross +22.50%
#6 Akedo Akedo +15.95%
#7 DoubleZero DoubleZero +14.89%
#8 Not in Employment, Education, or Training Not in Employment, Education, or Training +11.53%
#9 Fake World Assets Fake World Assets +10.34%
#10 Cap Cap +10.26%
Coin of the day
Islamic Coin Islamic Coin
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Notable Labs, Ltd. Notable Labs, Ltd.

Notable Labs, Ltd.

NTBL
Classement en actions #41091
Notable Labs, Ltd. operates as a clinical-stage therapeutic platform company,... Notable Labs, Ltd. operates as a clinical-stage therapeutic platform company, concentrating on creating predictive, personalized treatments for individuals battling cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), the company virtually tests potential cancer therapies to forecast an individual patient's likely response to a specific drug. The primary goal of the PPMP is to identify and qualify patients who are expected to respond favorably before they even begin treatment, thereby significantly accelerating the clinical development process for these specific patient groups. Notable Labs' current development pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor designed to treat acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes. Additionally, it features Fosciclopirox, a prodrug of ciclopirox, also aimed at acute myeloid leukemia. The company's headquarters are located in Foster City, California.
Prix de l'action
$0.0202
Dernière synchronisation: 2024-11-19
Capitalisation boursière
$44.67K
Changement (1 jour)
-0.49%
Changement (1 an)
0.00%
Pays
IL
Échange Notable Labs, Ltd. (NTBL)

Catégorie

Healthcare
Bénéfices pour Notable Labs, Ltd. (NTBL)
Bénéfices en Jun 2024 TTM : $-8.99M
Selon les derniers rapports financiers de Notable Labs, Ltd., les bénéfices actuels de l'entreprise sont de $-8.99M. En 2022, l'entreprise a réalisé un bénéfice de $-14.41M, une augmentation par rapport à celui de 2021 qui était de $-16.05M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Notable Labs, Ltd. de 2015 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
2026 (TTM) $-8.99M -20.23%
2023 $-11.26M -21.82%
2022 $-14.41M -10.25%
2021 $-16.05M -33.74%
2020 $-24.23M 24.90%
2019 $-19.40M -5.19%
2018 $-20.46M 101.80%
2017 $-10.14M -36.65%
2016 $-16.00M 7.48%
2015 $-14.89M 0.00%
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -58,807.85%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -21,810.07%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -33,552.61%
BE